TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates

分组1 - TELA Bio, Inc. reported a quarterly loss of $0.23 per share, which is an improvement from a loss of $0.53 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $17.65 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 24.25%, but showing a slight increase from $17 million in the same quarter last year [2] - TELA Bio shares have declined approximately 21.9% since the beginning of the year, contrasting with the S&P 500's decline of 3.5% [3] 分组2 - The earnings outlook for TELA Bio is mixed, with the current consensus EPS estimate for the coming quarter at -$0.30 on revenues of $21 million, and -$0.66 on revenues of $94.1 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which TELA Bio belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook [8] - TELA Bio has surpassed consensus EPS estimates only once in the last four quarters, indicating challenges in meeting market expectations [1][2]